Is GLIADEL® Wafer considered an experimental treatment?
No. GLIADEL® Wafer is commercially available in the U.S. for the treatment of GBM. Originally, only for recurrent GBM, but it is now also approved for use at the time of the initial surgery. • Has GLIADEL® Wafer helped recurrent GBM patients live longer? Yes. LIADEL® Wafer has been shown to extend the lives of patients with recurrent GBM. According to one study, 56% of the GBM patients receiving GLIADEL® Wafer during surgery to remove their tumors were still alive after 6 months, as opposed to 36% of patients who only had surgery. The same study showed that the median survival (the length of time half of the patients with GBM in the study survived) went from 20 weeks without GLIADEL® Wafer to 28 weeks with GLIADEL® Wafer – an increase of 41%. Your doctor will be able to give you a better assessment based on your individual situation. • Are there any side effects associated with GLIADEL® Wafer therapy? Yes. Chemotherapy has the potential to cause side effects. Certain side effects repor
